Format

Send to:

Choose Destination
See comment in PubMed Commons below
Leuk Res. 2014 Mar;38(3):334-9. doi: 10.1016/j.leukres.2013.12.009. Epub 2013 Dec 24.

The prevalence and prognostic value of concomitant eosinophilia in chronic graft-versus-host disease after allogeneic stem cell transplantation.

Author information

  • 1Department of Hematology, Copenhagen University Hospital, Copenhagen, Denmark. Electronic address: katrinekbm@gmail.com.
  • 2Department of Biostatistics, University of Copenhagen, Copenhagen, Denmark.
  • 3Department of Hematology, Copenhagen University Hospital, Copenhagen, Denmark.
  • 4Department of Hematology, Copenhagen University Hospital, Copenhagen, Denmark; Department of Hematology, Roskilde Hospital, Roskilde, Denmark.

Abstract

The prognostic significance of eosinophilia after myeloablative allogeneic stem cell transplantation (ASCT) remains to be established. Patients, whom developed chronic graft-versus-host disease (cGVHD) after ASCT, were included (n = 142). Eosinophil count was analyzed at cGVHD onset. We observed no significant association between EO and the grade of cGVHD, thrombocytopenia, nor extensive skin involvement. Importantly, we observed no significant association between cGVHD with concomitant eosinophilia and long-term clinical outcomes, and subgroup analyses revealed a considerable confounding effect of ongoing steroid treatment. In conclusion, we advocate that prognostic conclusions regarding cGVHD with concomitant eosinophilia after ASCT should be interpreted with caution.

Copyright © 2013 Elsevier Ltd. All rights reserved.

KEYWORDS:

Allogeneic stem cell transplantation; Chronic graft-versus-host disease; Clinical outcome; Eosinophilia; Glucocorticoids; Myeloablative

PMID:
24439053
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk